IRF4 and cMyc have drawn considerable attention as critical pro-survival factors for MM cells [11, 12], especially after unveiling the mechanisms of action for anti-MM effects of immunomodulatory agents (IMiDs), including lenalidomide and pomalidomide. This evidence concerns the gene MYC and Miyoshi myopathy.